Abstract:Abstract BACKGROUND AND AIMS A treat-to-target (TTT) strategy of aiming for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest. We sought to assess the feasibility of implementing TTT and improve its uptake in the Crohn’s and Colitis Foundation’s IBD Qorus learning health system (LHS). METHODS We examined an ‘intention to TTT’ for each eligible clinic visit (patients not in endoscopic remission on most recent evaluation) across a multi-center LHS over a 12-month period (November 2020-November 2021). ‘Intention to TTT’ (or TTT score) was defined as an affirmative response to all three of the following: (1) Was treat-to target discussed with patient?, (2) Was objective assessment for inflammation (endoscopy, radiology and/or fecal calprotectin) performed within the preceding 12m?, (3) Is there an intention to change treatment since target has not been reached? Over a 12-month breakthrough series (BTS) collaborative, we sought to improve implementation of TTT with monthly report cards, webinars, an active listserv and two all-Qorus learning sessions. Changes in rates of ‘intention to TTT’ were examined over 12 months, overall and at each site, with an earliest clinically meaningful signal of improvement defined a priori as 2% increase per month. In secondary analyses, we compared overall rates of achieving endoscopic remission and corticosteroid-free clinical remission in sites with improvement in rates of ‘intention to TTT’ relative to sites without improvement (only sites with valid data for 8/12 months). RESULTS Over 12 months, there were 7934 patient visits across 38 sites in the collaborative; patients in 37% visits (n=2913) were not in endoscopic remission at time of visit. Overall, rates of ‘intention to TTT’ increased from 23% at the beginning of the BTS, to 49% at the end of the BTS, corresponding to a clinically significant 2.4% per month increase in rates of implementing TTT (Figure 1). While rates of discussion of TTT (88% of eligible visits) and intending to adjust therapy (70% of eligible visits) were consistently high, there was a significant increase in objective evaluation for inflammation during the course of the BTS. There was considerable variability across sites in rates of ‘intention to TTT’. Comparing 9/14 sites with improvement in rates of implementing TTT vs. 5/14 sites without improvement, there were trends towards increasing rates of site-level endoscopic remission and steroid-free clinical remission (Figure 2). CONCLUSIONS Through a quality improvement initiative in a LHS, rates of ‘intention to TTT’ increased significantly over 12-months. This improvement in implementation of TTT was accompanied by increase in rates of achieving endoscopic remission and steroid-free clinical remission.

REAL WORLD IMPLEMENTATION OF TREAT-TO-TARGET IN PATIENTS WITH IBD IN A LEARNING HEALTH SYSTEM: AN IBD QORUS COLLABORATIVE STUDY

S1067 Treat-to-Target: A Comparison of Treatment and Patient Outcomes Between Academic and Private Practices in IBD Qorus

PATTERNS AND ASSOCIATED FACTORS OF OBJECTIVE INFLAMMATION ASSESSMENT TO TREAT-TO-TARGET: DATA FROM THE IBD QORUS COLLABORATIVE

Treat to target in Crohn’s disease: A practical guide for clinicians

P659 Prognostic markers in Treat-to-Target for Crohn’s Disease- an Asian institution’s experience

P344 Achieving Crohn's Disease treatment targets following the STRIDE-II recommendations in clinical practice

S1456 Treat to Target Recommendations and Adherence in Inflammatory Bowel Disease: Patient Experiences and Perspectives

P574 Incidence and Indicators of Suboptimal Response to Tumour Necrosis Factor Antagonist Therapy in Chinese Patients with Inflammatory Bowel Disease: Results from the EXPLORE Study

EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA

OP0250 INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET FOR SYSTEMIC LUPUS ERYTHEMATOSUS VIA EMPOWERING PATIENTS: A COHORT STUDY FROM CHINA BY SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

Towards a Better Implementation of Treat-to-Target Strategy in Rheumatoid Arthritis: A Comparison of Two Real-World Cohorts

Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review

DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial

P978 Changing therapy to achieve endoscopic healing in asymptomatic patients with IBD: When is perfect the enemy of good?

P286 Variation of outcomes in inflammatory bowel disease at ten Australasian centres - Crohn's Colitis Cure (CCC) Data Insights Program

Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East

Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease

Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD

Challenges in implementing treat-to-target in rheumatoid arthritis: a perspective from Brazilian rheumatologists

P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients